132067-41-5

Basic information

• Product Name: Boc-4-bromo-DL-phenylalanine methyl ester
• Synonyms: Boc-4-bromo-DL-phenylalanine methyl ester;methyl 3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate;3-(4-BROMOPHENYL)-2-((TERT-BUTOXYCARBONYL)AMINO)PROPANOATE(WX191488)
• CAS NO: 132067-41-5
• Molecular Formula: C₁₅H₂₀BrNO₄
• Molecular Weight: 358.2276
• Mol File: 132067-41-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Boc-4-bromo-DL-phenylalanine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-4-bromo-DL-phenylalanine methyl ester(132067-41-5)
• EPA Substance Registry System: Boc-4-bromo-DL-phenylalanine methyl ester(132067-41-5)

Safety Data

• Hazardous Substances Data: 132067-41-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Biochemical Research:
Boc-4-bromo-DL-phenylalanine methyl ester is utilized as a building block in peptide synthesis for the development of pharmaceuticals and biochemical research. Its Boc protecting group ensures the stability of the compound during synthesis, while the 4-bromo group provides a site for further modification, enhancing the compound's potential for creating novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, Boc-4-bromo-DL-phenylalanine methyl ester serves as a key intermediate for the synthesis of various organic compounds. Its unique structure allows for a wide range of reactions, making it a valuable component in the creation of complex organic molecules and advanced materials.
Used in Drug Development:
Boc-4-bromo-DL-phenylalanine methyl ester is employed as a precursor in the development of new drugs. Its versatility and reactivity enable the synthesis of diverse pharmaceutical compounds with potential therapeutic applications, contributing to the advancement of medicine and healthcare.

Upstream product

• 132153-48-1 N-(tert-Butyloxycarbonyl)-4-bromo-DL-phenylalanine 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 14091-15-7 p-bromo-DL-phenylalanine 
• 166967-59-5 ethyl 2-amino-3-(4-bromophenyl) propanoate 
• 99359-32-7 C₁₀H₁₂BrNO₂*(x)ClH 
• 444726-88-9 H-Phe(4-Br)-OMe hydrochloride 

Downstream Products

• 132067-42-6 N-(tert-Butyloxycarbonyl)-4-(diethoxyphosphono)-DL-phenylalanine methyl ester 
• 874184-03-9 4-{(1E)-3-[6,7-dimethoxy-3-(4-methoxyphenyl)-2-oxoquinolin-1(2H)-yl]prop-1-enyl}-N-[(1,1-dimethylethoxy)carbonyl]phenylalanine 
• 120667-22-3 4-Phosphono-DL-phenylalanine 
• 1333114-52-5 tert-butyl (1-(4-bromophenyl)-3-hydroxypropan-2-yl)carbamate 
• 1333114-53-6 methyl 2-((3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propoxy)methyl)-benzoate 
• 1333114-54-7 tert-butyl (1-(4-bromophenyl)-3-((2-(hydroxymethyl)benzyl)oxy)propan-2-yl)carbamate 
• 1333114-55-8 tert-butyl (1-((2-(bromomethyl)benzyl)oxy)-3-(4-bromophenyl)propan-2-yl)carbamate 
• 1333114-57-0 1-((2-(bromomethyl)benzyl)oxy)-3-(4-bromophenyl)propan-2-amine trifluoroacetate 
• 1333114-59-2 4-(4-bromobenzyl)-5-((2-methoxyphenyl)sulfonyl)-3,4,5,6-tetrahvdro-1H-benzo-[f][1,4]oxazocine 
• 1333114-58-1 4-(4-bromobenzyl)-3,4,5,6-tetrahydro-1H-benzo[f][1,4]oxazocine 
• 1616735-89-7 C₂₀H₂₅N₅O₄ 
• 1616735-97-7 C₁₄H₁₅N₅O₂*C₂HF₃O₂ 
• 864876-00-6 tert-butyl (3-(4-bromophenyl)-1-(hydroxyamino)-1-oxopropan-2-yl)carbamate 

Relevant articles and documents

NOVEL AMINOPEPTIDASE INHIBITORS AND METHODS OF USE

An aminopeptidase inhibitor compound comprising a biaryl, hydroxamic acid based core of formula: wherein X is a 5 or 6-membered ring, and including pharmaceutically acceptable salts and solvates thereof.

Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PfA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics.

TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF

Described herein are tetrazine derivatives and efficient synthetic methods of synthesis thereof using elimination-Heck cascade reaction. Provided herein is the synthesis of conjugated tetrazines from the tetrazine derivatives. Also provided herein are met

In situ synthesis of alkenyl tetrazines for highly fluorogenic bioorthogonal live-cell imaging probes

In spite of the wide application potential of 1,2,4,5-tetrazines, particularly in live-cell and in vivo imaging, a major limitation has been the lack of practical synthetic methods. Here we report the in situ synthesis of (E)-3-substituted 6-alkenyl-1,2,4

NOVEL COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASE

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of formula (1) or (2) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

Synthesis of 4-phosphono- and of 4-(phosphonomethyl)-dl-phenylalanine, two analogues of O-phosphotyrosine

:4-Phosphono-DL-phenylalanine 1 was synthetized from 4-bromo-DL-phenylalanine or from 4-(bromomethyl)-bromobenzene ; 4-(phosphonomethyl)-DL-phenylalanine 14 was prepared from methyl p-toluate. The interest of these phosphonic analogues arises from their possible interference in the metabolism of O-phosphotyrosine.